United States Patent 8,501,819: Scope, Claim Analysis, Expiration, and Mechlorethamine Patent Landscape
U.S. Patent No. 8,501,819 protects a narrow topical treatment method using mechlorethamine, also known as bis-(2-chloroethyl)methylamine, in a non-aqueous composition containing an ethoxy-diglycol-type excipient. The independent claim requires four central elements: the active ingredient, a non-aqueous vehicle, a defined concentration range, and treatment of psoriasis, mycosis fungoides, or alopecia.
The patent is closely associated with Valchlor, the mechlorethamine hydrochloride topical gel marketed by Actelion Pharmaceuticals, a subsidiary of Johnson & Johnson’s Janssen organization. Its principal commercial value lies in the vehicle and treatment-method limitations rather than in broad coverage of mechlorethamine itself.
What does U.S. Patent 8,501,819 claim?
Claim 1 is a method-of-treatment claim. A potentially infringing product or use must satisfy every limitation:
| Claim element |
Required scope |
| Patient |
A person |
| Administration |
Topical application to affected skin |
| Composition |
Non-aqueous |
| Active ingredient |
Bis-(2-chloroethyl)methylamine or a pharmaceutically acceptable salt |
| Active concentration |
About 0.001% to about 2.0% by weight |
| Excipient |
HOCH2CH2OCH2CH2OR79 |
| R79 limitation |
Linear alkyl group containing 1-6 carbon atoms |
| Disease |
Psoriasis, mycosis fungoides, or alopecia |
The claim does not cover every topical mechlorethamine formulation. It requires the specified chemical class of excipient and one of the listed diseases.
The active ingredient is mechlorethamine, historically used as an antineoplastic alkylating agent. The claim covers both the free base and pharmaceutically acceptable salts, subject to the dependent-claim limitations where applicable.
How broad is the independent claim of Patent 8,501,819?
Claim 1 is broad in concentration but narrow in formulation architecture and indication.
The active concentration ranges from approximately 0.001% to 2.0% by weight. That range includes concentrations materially below and above the concentration commonly associated with Valchlor. Claim 5 narrows the range to approximately 0.01% to 0.04%, which is directed toward the commercially relevant low-dose formulation range.
The excipient limitation is more restrictive. The formula:
HOCH2CH2OCH2CH2OR79
describes a diethylene glycol monoalkyl ether. The permitted R79 group is a linear C1-C6 alkyl group. The claim therefore covers compounds such as:
- Diethylene glycol monomethyl ether
- Diethylene glycol monoethyl ether, commonly called ethoxy diglycol
- Diethylene glycol monopropyl ether
- Diethylene glycol monobutyl ether
- Other linear C5-C6 analogues within the claim
A formulation using propylene glycol, polyethylene glycol, mineral oil, water, or a different solvent would not literally satisfy the excipient limitation unless another component independently met the claimed formula.
The word “about” creates a potential infringement boundary issue. Courts generally interpret “about” according to the intrinsic evidence, including the specification, examples, analytical precision, and technical meaning in the field. A formulation just outside a numerical range may still create litigation risk if the evidence supports a tolerance around the stated value.
What do dependent claims 2 through 10 add?
The dependent claims create narrower positions that are easier to map to a commercial product but potentially easier to design around.
| Claim |
Added limitation |
| 2 |
Active ingredient is an acid-addition or base-addition salt |
| 3 |
Acid-addition salt is HCl, HBr, HI, H2SO4, or HNO3 |
| 4 |
Excipient is the C2 compound, ethoxy diglycol |
| 5 |
Active concentration is about 0.01%-0.04% |
| 6 |
Acid-addition salt is the hydrochloride salt |
| 7 |
Mechlorethamine hydrochloride plus ethoxy diglycol |
| 8 |
Disease is mycosis fungoides |
| 9 |
Disease is psoriasis |
| 10 |
Disease is alopecia |
Claim 7 is the most commercially focused dependent claim. It combines mechlorethamine hydrochloride with ethoxy diglycol. A topical product matching that combination and used for one of the diseases in claim 1 would present the clearest literal infringement risk.
Claims 8, 9, and 10 divide the disease limitation into separate indications. They are important because an ANDA applicant may certify differently depending on the proposed labeling and whether the use is carved out.
What formulations are protected by U.S. Patent 8,501,819?
The patent protects non-aqueous topical compositions in which the active ingredient is dissolved, dispersed, or otherwise formulated with the claimed diethylene glycol monoalkyl ether excipient.
The strongest claim overlap occurs where a product contains:
- Mechlorethamine hydrochloride;
- Ethoxy diglycol;
- Approximately 0.01%-0.04% mechlorethamine by weight;
- A non-aqueous gel or semisolid vehicle; and
- Labeling or use for mycosis fungoides, psoriasis, or alopecia.
A formulation can avoid literal infringement by changing one claim element, such as:
- Using an aqueous formulation;
- Replacing ethoxy diglycol with a nonclaimed solvent;
- Using a different active concentration outside the properly construed range;
- Omitting mechlorethamine hydrochloride in favor of another salt or formulation;
- Avoiding the claimed indications in the proposed label.
A design-around is not automatically safe. The doctrine of equivalents can create risk where a substituted excipient performs substantially the same function in substantially the same way to achieve substantially the same result. Prosecution-history estoppel may limit that theory if the patent owner narrowed the excipient or concentration scope during prosecution.
When does Patent 8,501,819 expire?
The commonly reported expiration date for U.S. Patent 8,501,819 is May 20, 2029, subject to any applicable patent-term adjustment or other statutory modification recorded in the official patent file and Orange Book listing.
| Milestone |
Date or status |
| U.S. patent |
8,501,819 |
| Grant date |
August 6, 2013 |
| Expected patent expiration |
May 20, 2029 |
| Patent type |
Method of treatment |
| Primary product association |
Valchlor |
| Relevant active |
Mechlorethamine hydrochloride |
| FDA product |
Valchlor topical gel |
| FDA approval |
August 2013 |
The patent’s commercial blocking period extends beyond FDA approval because the patent term is calculated from the relevant application-priority framework, not from the date of product launch.
The patent does not receive a separate patent term extension merely because Valchlor was approved. Patent term extension depends on statutory eligibility, regulatory review periods, and an approved product-specific application. The relevant Orange Book and USPTO records control the operative term.
What is the Orange Book status of Patent 8,501,819?
Patent 8,501,819 has been associated with Valchlor, a prescription topical gel containing mechlorethamine hydrochloride. The patent listing is significant because an ANDA applicant relying on Valchlor must address listed patents through one of the Hatch-Waxman certification pathways.
The relevant certifications are:
- Paragraph I: No patent information has been submitted.
- Paragraph II: The listed patent has expired.
- Paragraph III: The applicant will not market before patent expiration.
- Paragraph IV: The listed patent is invalid, unenforceable, or will not be infringed.
For a patent with a 2029 expiration date, Paragraph III would defer launch until expiration. A Paragraph IV certification can create litigation under 35 U.S.C. § 271(e)(2), with a potential 30-month FDA approval stay if the patent holder timely files suit.
An applicant may also pursue a section viii statement, or “skinny label,” by excluding patented indications from its labeling. That strategy is more difficult where the listed patent claims the composition and the method jointly, because a generic product may still be used for a patented indication even if the indication is omitted from the label.
Which companies are challenging the Valchlor patent estate?
Public patent challenges to Valchlor would normally arise through ANDA filings and subsequent Hatch-Waxman litigation. The relevant parties may include the NDA holder, its commercial affiliates, generic applicants, and manufacturers supplying the ANDA product.
Patent litigation risk should be assessed separately for each patent listed for Valchlor. A Paragraph IV case involving Patent 8,501,819 does not necessarily resolve later-issued patents covering the formulation, manufacturing process, stability profile, or delivery system.
The key legal questions in a challenge to Patent 8,501,819 would include:
- Whether the claimed composition was obvious from earlier mechlorethamine formulations;
- Whether the non-aqueous vehicle produced an unexpected stability or tolerability result;
- Whether the claims are adequately supported across the full 0.001%-2.0% range;
- Whether the specification enables every claimed excipient and concentration;
- Whether “about” creates an indefinite numerical boundary;
- Whether the claimed diseases are adequately supported by clinical or experimental evidence;
- Whether the proposed generic product meets the non-aqueous and excipient limitations.
A generic applicant may attack validity under obviousness, written description, enablement, and indefiniteness. A noninfringement position would likely focus on the vehicle, concentration, salt form, or proposed indication.
What related patents cover mechlorethamine topical products?
Patent 8,501,819 is part of a broader Valchlor-related patent estate. Publicly reported U.S. patents associated with topical mechlorethamine include:
| Patent |
General relevance |
Reported expiration |
| U.S. 8,501,819 |
Topical treatment method using non-aqueous mechlorethamine composition and diethylene glycol ether |
May 20, 2029 |
| U.S. 9,566,223 |
Related topical mechlorethamine composition and formulation claims |
Approximately 2029 or later, depending on patent-term records |
| Later continuation or related patents |
Potential formulation, stability, process, or use coverage |
Patent-specific |
The family structure matters. A continuation may issue with claims materially different from those in Patent 8,501,819. One patent may claim a method, while another claims the composition itself. A third may focus on a particular gel, solvent ratio, manufacturing sequence, or stability characteristic.
A freedom-to-operate review therefore cannot stop at Patent 8,501,819. It must compare the proposed product against every unexpired family member, Orange Book-listed patent, and relevant patent application with potentially enforceable continuation claims.
How strong is the patent estate for Valchlor?
Patent 8,501,819 has moderate commercial strength because it combines a known active ingredient with a specific formulation vehicle and defined disease uses.
Its strengths are:
- It targets the commercial dosage form rather than only the active ingredient.
- The claimed excipient is chemically specific.
- The low-dose range in claims 5 and 7 maps closely to a commercial topical product.
- The patent covers several disease categories.
- Method claims can create infringement exposure based on the labeled use of an ANDA product.
Its weaknesses are:
- Mechlorethamine was known before the patent.
- Topical treatment of skin disorders was known.
- Solvent selection and non-aqueous formulation may be vulnerable to an obviousness challenge.
- The broad concentration range may raise enablement or written-description questions.
- A generic manufacturer may avoid literal infringement through a different vehicle.
- Claims 8-10 are limited to specified diseases and may be vulnerable to skinny-label strategies.
The commercial strength is higher when Patent 8,501,819 is combined with later patents covering the product’s specific gel composition or manufacturing process. A single-patent landscape would understate the launch barriers.
Does biosimilar law affect Valchlor?
No. Valchlor is a small-molecule drug, not a biologic. Biosimilar approval under the Public Health Service Act does not apply.
The relevant competitive pathway is an abbreviated new drug application under section 505(j) of the Federal Food, Drug, and Cosmetic Act. Generic applicants must address pharmaceutical equivalence, bioequivalence, labeling, manufacturing controls, and listed patents through Hatch-Waxman certifications.
The principal regulatory risk is therefore generic entry, not biosimilar substitution.
What FDA exclusivity applies to Valchlor?
Valchlor’s regulatory protection is distinct from the Patent 8,501,819 term.
The FDA approved Valchlor for the topical treatment of stage IA and IB mycosis fungoides in adults who received prior skin-directed therapy. The product contains mechlorethamine hydrochloride in a topical gel. The active ingredient itself was not a new molecular entity in 2013, so five-year NCE exclusivity would not normally apply.
Any orphan-drug, clinical-investigation, pediatric, or other regulatory exclusivity must be evaluated from FDA’s product-specific records. Regulatory exclusivity can block or delay approval even after a patent expires, but it does not expand the patent claims.
What litigation and settlement issues affect generic entry?
A Paragraph IV filing can trigger a patent case before the U.S. District Court. The case may seek:
- A declaration that Patent 8,501,819 is invalid;
- A declaration of noninfringement;
- A declaration of unenforceability;
- An injunction delaying commercial launch;
- A judgment establishing the patent’s expiration date.
Settlement agreements may provide a licensed entry date before patent expiration, supply arrangements, royalties, or restrictions on product labeling. Any such agreement may be subject to Federal Trade Commission review and Medicare-related reporting requirements.
The most consequential launch scenarios are:
| Scenario |
Likely commercial result |
| Paragraph III certification |
Launch after the listed patent expires |
| Paragraph IV with patent-holder victory |
Launch delayed until expiration or settlement date |
| Paragraph IV with generic victory |
Earlier launch, subject to other patents |
| Skinny-label approval |
Limited launch for unpatented indications |
| Formulation design-around |
Possible launch if no other patent claims the substitute vehicle |
| License settlement |
Entry date depends on negotiated terms |
What is the geographic coverage of Patent 8,501,819?
The patent is enforceable only in the United States. Foreign counterparts may exist, but their scope, prosecution history, validity, and expiration dates differ.
A global launch assessment requires separate review of national patents in Europe, Canada, Japan, Australia, and other markets. U.S. approval and U.S. patent status do not establish freedom to operate elsewhere.
Manufacturing outside the United States can still create U.S. exposure if the product is imported into the United States, sold in the United States, or used in a way covered by an enforceable U.S. method claim.
Key Takeaways
- Patent 8,501,819 claims a method of treating psoriasis, mycosis fungoides, or alopecia with topical non-aqueous mechlorethamine.
- The critical vehicle limitation is a diethylene glycol monoalkyl ether, with ethoxy diglycol expressly covered.
- Claim 7 most closely targets a commercial mechlorethamine hydrochloride and ethoxy diglycol formulation.
- The reported expiration date is May 20, 2029.
- The patent is associated with Valchlor and should be analyzed with related formulation and continuation patents.
- Generic competition would proceed under Hatch-Waxman, not the biosimilar pathway.
- A Paragraph IV challenge would likely focus on obviousness, enablement, written description, indefiniteness, and formulation noninfringement.
- A different solvent, aqueous vehicle, concentration, salt, or carved-out indication may reduce infringement risk but does not eliminate exposure to related patents.
- U.S. patent status does not determine foreign launch freedom.
- The patent’s commercial value depends on the cumulative Valchlor estate, not Patent 8,501,819 in isolation.
FAQs About U.S. Patent 8,501,819 and Mechlorethamine
Can a generic use a solvent other than ethoxy diglycol?
Potentially. A substitute solvent outside the claimed diethylene glycol monoalkyl ether formula may avoid literal infringement of claim 1. The substitute must also be evaluated against related composition patents and the doctrine of equivalents.
Does Patent 8,501,819 cover all uses of mechlorethamine for mycosis fungoides?
No. It covers the claimed topical, non-aqueous composition and excipient combination within the specified concentration range. It does not broadly cover every dosage form, vehicle, concentration, or route of administration.
Can a generic launch for psoriasis while excluding mycosis fungoides?
The regulatory and patent analysis depends on the full claim set and Orange Book listings. Excluding one patented indication may reduce method-of-use risk, but the remaining label and composition may still fall within claim 1 or another listed patent.
Is ethoxy diglycol the same as diethylene glycol monoethyl ether?
Yes. Ethoxy diglycol is commonly used as the INCI and commercial name for diethylene glycol monoethyl ether, the C2 compound specified in claims 4 and 7.
Does expiration of Patent 8,501,819 guarantee generic entry?
No. Generic entry may remain blocked by other unexpired formulation, process, stability, or method-of-use patents, FDA exclusivity, regulatory requirements, or a settlement agreement.
References
-
Actelion Pharmaceuticals Ltd. (2013). Valchlor (mechlorethamine) gel, 0.016% prescribing information. U.S. Food and Drug Administration.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
United States Patent and Trademark Office. (2013). U.S. Patent No. 8,501,819: Compositions and methods for treatment of skin disorders. U.S. Department of Commerce.
-
United States Patent and Trademark Office. (2017). U.S. Patent No. 9,566,223: Topical compositions comprising mechlorethamine. U.S. Department of Commerce.
-
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355.
-
Hatch-Waxman Act, 35 U.S.C. §§ 271(e)(2), 355(j).
